Studies from Colorado State University add new findings in the area of tuberculosis vaccines
2007 NOV 19 -- Research findings, 'A mutant of Mycobacterium tuberculosis lacking the 19-kDa lipoprotein Rv3763 is highly attenuated in vivo but retains potent vaccinogenic properties,' are discussed in a new report. According to recent research from the United States, "A mutant of Mycobacterium tuberculosis (Delta 19) lacking the 19-kDa lipoprotein grows well in culture in vitro but was shown here to be essentially incapable of any significant replication in mice, even in mice lacking the gamma interferon gene." "Despite this, mice inoculated with Delta 19 were equally protected against an aerosol delivered challenge with M. tuberculosis compared to the conventional BCG vaccine. Cellular responses, including the generation of activated CD4 and CD8 cells secreting gamma interferon, were produced in similar numbers, and lung cells, particularly dendritic macrophages, exhibited high levels of Class-II MHC expression," wrote M. Henao-Tamayo and colleagues, Colorado State University. The researchers concluded: "These data show that despite being highly attenuated, the Delta 19 mutant strongly retained vaccinogenic properties." Henao-Tamayo and colleagues published their study in Vaccine (A mutant of Mycobacterium tuberculosis lacking the 19-kDa lipoprotein Rv3763 is highly attenuated in vivo but retains potent vaccinogenic properties. Vaccine, 2007;25(41):7153-9). For additional information, contact M. Henao-Tamayo, Mycobacteria Research Laboratories, Dept. of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80524 USA.. Publisher contact information for the journal Vaccine is: Elsevier Science Ltd., the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. Keywords: United States, Fort Collins, Tuberculosis Vaccines, Biotechnology, Cutaneous Tuberculosis, Interferon, Mycobacteria, Mycobacterium Tuberculosis, Vaccines. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
